Status:

TERMINATED

Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Conditions:

Diabetic Neuropathies

Pain

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy.

Eligibility Criteria

Inclusion

  • Diabetes type 1 or 2
  • Painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months

Exclusion

  • Major Depression
  • Uncontrolled diabetes

Key Trial Info

Start Date :

March 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

408 Patients enrolled

Trial Details

Trial ID

NCT00283842

Start Date

March 1 2006

End Date

June 1 2008

Last Update

October 24 2011

Active Locations (51)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (51 locations)

1

Mesa, Arizona, United States, 85210

2

Peoria, Arizona, United States, 85381

3

Phoenix, Arizona, United States, 85016

4

Encino, California, United States, 91316